The phase 2 study, called KarMMa, enrolled 140 patients with active myeloma after receiving at least 3 previous therapies, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 antibody. Among the 128 treated patients, the median age was 61 years and the median time since diagnosis was 6 years.
NEW YORK, NY / ACCESSWIRE / February 28, 2021 / Jakubowitz Law announces that securities fraud class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies who purchased shares within the class periods listed below. Shareholders interested in representing the class of wronged shareholders have until the lead plaintiff deadline to petition the court.
After ten consecutive days of losses, Bluebird bio (BLUE) has risen for the third consecutive day with a~10.6% gaintoday.Last week, the company announced that it has paused two...
bluebird bio, Inc. (NASDAQ:BLUE) - Research analysts at Wedbush lowered their FY2022 earnings per share estimates for shares of bluebird bio in a research report issued to clients and investors on Wednesday, February 24th. Wedbush analyst D. Nierengarten now expects that the biotechnology company
For patients with certain blood cancers, a stem cell transplant can often be a curative treatment. However, it is also a complex process riddled with severe toxicities and high rates of relapse or failure. These issues are at least part of the reason why only about 60% of cancer
With more than 2.6 billion daily users, it's no secret that Facebook (NASDAQ: FB) reaches a lot of people around the world across Facebook, Messenger, Instagram, and WhatsApp. Building on its COVID-19 information center, the tech stock recently announced a big push to provide aut
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb 26, 2021-- bluebird bio, Inc. (NASDAQ: BLUE) today announced that members of the management team will participate in the Cowen 41 st Annual Health Care Conference, Wednesday, March 3, at 2:40 p.m. ET.
Panos Englezos, President of the Thalassaemia International Federation, Cyprus To mark Rare Disease Day 2021, gene therapy company bluebird bio has joined forces with a number of leading patient organisations and clinicians to highlight the personal stories of European patients who are living with the rare inherited blood disorder thalassaemia.
7 hours ago (Feb 25, 2021 08:47PM ET) RBC Capital analyst Luca Issi maintained a Hold rating on bluebird bio on Wednesday, setting a price target of $37, which is approximately 42.75% above the present share price of $25.92. Issi expects bluebird bio to post earnings per share (EPS) of -$2.94 for the first quarter of 2021.
Executives at Bluebird bio on Thursday gave investors listening to a conference hosted by bank SVB Leerink an update on their investigation into two recent cancer cases in a study of the company's gene therapy for sickle cell disease.
Global Thalassemia Market Size, Status and Forecast 2021-2027 , Covid 19 Outbreak Impact research report added by Report Ocean, is an in-depth analysis of market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
NEW YORK, NY / ACCESSWIRE / February 25, 2021 /WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of bluebird bio, Inc. (NASDAQ:BLUE) between May 11, 2020 and November 4, 2020, inclusive (the "Class Period").
Bluebird bio Inc.'s leadership allegedly misled shareholders about the license application for its sickle cell drug and the "forseeable impact" of coronavirus-related disruptions, a derivative suit filed in federal court in Delaware says.
bluebird bio, Inc. (NASDAQ:BLUE) - Research analysts at Wedbush lowered their FY2022 earnings per share estimates for shares of bluebird bio in a research report issued to clients and investors on Wednesday, February 24th. Wedbush analyst D. Nierengarten now expects that the biotechnology company
VIVEbiotech has responded to the high demand for lentiviral vectors in the cell and gene therapy space by expanding its facilities. While no financial details have been disclosed, the Spanish contract development manufacturing organization (CDMO) said it is ramping up its manufacturing capacity and processes enabling it to respond to lentiviral demand.
The U.S. Food and Drug Administration (FDA) has pushed bluebird bio's voluntary pause to a regulator-demanded clinical hold for all LentiGlobin gene therapy trials, following last week's announcement that two enrolled sickle cell disease (SCD) patients developed acute myeloid leukemia (AML) and myelodysplastic syndrome, respectively.
CAMBRIDGE, Mass.--()--Results from the pivotal Phase 2 KarMMa study evaluating the efficacy and safety of bluebird bio, Inc. (Nasdaq: BLUE) and Bristol Myers Squibb's (NYSE: BMY) investigational B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T cell immunotherapy, idecabtagene vicleucel (ide-cel; bb2121), in adult patients with relapsed and refractory multiple myeloma (RRMM) who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti-CD38 antibody, were published today in The New England Journal of Medicine.
The New England Journal of Medicine has published the Phase 2 study results for CAR T cell immunotherapy, idecabtagene vicleucel (ide-cel; bb2121) developed by bluebird...
bluebird bio Inc (BLUE) stock is lower by -63.30% over the last 12 months, and the average rating from Wall Street analysts is a Buy. InvestorsObserver's proprietary ranking system, gives BLUE stock a score of 33 out of a possible 100. That r
New York, New York--(Newsfile Corp. - February 24, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of bluebird bio, Inc. ("bluebird") (NASDAQ: BLUE) between May 11, 2020 and November 4, 2020.